文献速递淋巴瘤

MYC与BCL-2蛋白共表达对弥漫大B细胞淋巴瘤患者预后的影响:倾向性评分匹配分析

[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

回顾性收集2015至2018年北京协和医院223例初治弥漫大B细胞淋巴瘤患者,将75例MYC/BCL-2高表达者归为双表达组,经倾向性评分1∶1匹配从148例非双表达者中选出75例对照。匹配后两组3年总生存与无进展生存差异均无统计学意义,但R-CHOP方案亚组中双表达组3年总生存与无进展生存均显著较差。多因素分析显示双表达不是独立预后因素。

要点

  • 倾向性评分匹配后双表达组与非双表达组3年总生存率、无进展生存率差异均无统计学意义。
  • R-CHOP方案亚组中双表达患者3年总生存率与无进展生存率均显著低于非双表达患者。
  • 多因素分析中年龄、Ann Arbor分期、细胞起源分型、中枢神经系统预防及移植是独立影响因素。

核心结论

  • MYC/BCL-2蛋白双表达在R-CHOP方案治疗下与不良预后显著相关,但在DA-EPOCH-R、移植等治疗方案下,双表达对弥漫大B细胞淋巴瘤的不良预后影响在一定程度上得到消除。

研究设计与样本

  • 回顾性收集2015至2018年北京协和医院血液科治疗且具有可用病理结果的223例初治弥漫大B细胞淋巴瘤患者。
  • 75例MYC/BCL-2高表达患者归为双表达组,从148例非双表达患者中按年龄、国际预后指数评分、治疗选择等因素进行倾向性评分1∶1匹配,选出75例作为对照组。

主要发现

  • 倾向性评分匹配后双表达组与非双表达组3年总生存率分别为(69.8±5.5)%与(77.0±4.9)%(P=0.225),差异无统计学意义。
  • 倾向性评分匹配后双表达组与非双表达组3年无进展生存率分别为(60.7±5.8)%与(65.3±5.5)%(P=0.390),差异无统计学意义。
  • R-CHOP方案亚组中双表达组与非双表达组3年总生存率分别为(61.3±7.5)%与(77.2±5.6)%(P=0.027),双表达组较低。
  • R-CHOP方案亚组中双表达组与非双表达组3年无进展生存率分别为(52.1±7.5)%与(70.6±6.0)%(P=0.040),双表达组较低。
  • 多因素Cox回归分析显示年龄、Ann Arbor分期、细胞起源分型、是否进行中枢神经系统预防、是否进行移植是弥漫大B细胞淋巴瘤患者预后的独立影响因素(P值均<0.05),MYC/BCL-2蛋白双表达不是预后的影响因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: We investigated the impact of MYC/BCL-2 protein co-expression on the prognosis of diffuse large B-cell lymphoma (DLBCL) patients and observed whether double expression (DE) remains an independent poor prognostic factor in DLBCL after the addition of therapeutic factors such as DA-EPOCH-R, central prophylaxis, and transplantation. Methods: Available pathological findings were retrospectively collected from 223 DLBCL patients at the Peking Union Medical College Hospital from 2015 to 2018. Seventy-five patients with high MYC/BCL-2 expression were categorized as the DE group. From the 148 non-DE patients, 75 DLBCL patients were selected as the control group, using a 1∶1 matching on propensity scores for age, international prognostic index score, treatment choice, and etc. The differences in overall survival (OS) and progression-free survival (PFS) between the two groups were compared. Results: The 3-year OS was (69.8±5.5) % for the DE group and (77.0±4.9) % for the non-DE group (P=0.225) , while the 3-year PFS was (60.7±5.8) % and (65.3±5.5) % , respectively (P=0.390) . Subgroup analysis in patients treated with the R-CHOP regimen revealed that for the DE and non-DE patients, the 3-year OS was (61.3±7.5) % and (77.2±5.6) % (P=0.027) , and the 3-year PFS was (52.1±7.5) % and (70.6±6.0) % (P=0.040) , respectively. Multivariate analysis showed that age, stage of Ann Arbor, COO staging, whether central prophylaxis was performed, and whether transplantation was performed were significant independent risk factors of the prognosis of DLBCL patients (P<0.05) . On the other hand, MYC/BCL-2 protein double expression was not significantly associated with prognostic outcomes. Conclusion: MYC/BCL-2 protein double expression was significantly associated with poor prognosis under R-CHOP regimen treatment, but the poor prognostic impact of DE on DLBCL was eliminated under intensive regimens such as DA-EPOCH-R and transplantation. 目的: 探究MYC/BCL-2蛋白双表达对弥漫大B细胞淋巴瘤(DLBCL)患者预后的影响,观察纳入DA-EPOCH-R(利妥昔单抗+依托泊苷+泼尼松+长春新碱+环磷酰胺+表阿霉素)、中枢神经系统预防治疗、移植等治疗因素后,双表达是否仍是DLBCL的独立预后不良因素。 方法: 回顾性收集2015-2018年在北京协和医院血液科治疗且具有可用病理结果的223例初治DLBCL患者,75例MYC/BCL-2高表达的患者归为双表达组,从148例非双表达的患者中,应用倾向性评分(PSM),根据年龄、国际预后指数(IPI)评分、治疗选择等因素进行1∶1匹配,筛选出75例作为对照组,比较两组患者总生存(OS)及无进展生存(PFS)等方面的差异。 结果: PSM后双表达组和非双表达组的3年OS率分别为(69.8±5.5)%及(77.0±4.9)%(P=0.225),3年PFS率分别为(60.7±5.8)%及(65.3±5.5)%(P=0.390),差异均无统计学意义。R-CHOP方案(利妥昔单抗+环磷酰胺+阿霉素+长春新碱+泼尼松)治疗的亚组分析显示,双表达和非双表达患者的3年OS率分别为(61.3±7.5)%及(77.2±5.6)%(P=0.027),3年PFS率分别为(52.1±7.5)%及(70.6 ± 6.0)%(P=0.040),差异均具有统计学意义。多因素Cox回归分析显示年龄、Ann Arbor分期、细胞起源(COO)分型、是否进行中枢神经系统预防、是否进行移植是DLBCL患者预后的独立影响因素(P值均<0.05),而MYC/BCL-2蛋白双表达不是预后的影响因素。 结论: MYC/BCL-2蛋白双表达在R-CHOP方案治疗下与不良预后显著相关,但在DA-EPOCH-R、移植等治疗方案下,双表达对DLBCL的不良预后影响在一定程度上得到消除。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhan J, Yang SJ, Zhang W, et al. [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35231992. doi:10.3760/cma.j.issn.0253-2727.2022.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。